Wedbush added Argenx (ARGX) to the firm’s Best Ideas List as it believes the company is uniquely positioned to deliver sustained, market-leading growth in the autoimmune space, driven by continued expansion of Vyvgart and an emerging pipeline of assets that can sustain long-term momentum. Wedbush has an Outperform rating on the shares with a price target of $715.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx pullback brings ‘attractive buying opportunity,’ says Citi
- Argenx Se: Strong Growth Prospects and Attractive Buying Opportunity Amid Vyvgart Expansion and Upcoming Catalysts
- Argenx price target lowered to $699 from $701 at Citizens JMP
- Argenx upgraded to Outperform from Neutral at Baird
- Argenx Se: Buy Rating Affirmed Amid Pricing Strategy Confidence and Promising Growth Prospects